• 1
    Collins PW, Hirsch S, Baglin TP et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood 2007; 109: 18707.
  • 2
    Baudo F, De Cataldo F. Acquired haemophilia in the elderly. In: BalducciL, ErshlerW, De GaetanoG eds. Blood Disorders in the Elderly. Cambridge: Cambridge University Press, 2007: 389407.
  • 3
    Baudo F, Mostarda G, De Cataldo F. Acquired factor VIII and factor IX inhibitors: survey of the Italian Haemophilia Centers (AICE). Haematologica, 2003; 88(Suppl. 12): 939.
  • 4
    Sumner MJ, Geldziler BD, Pedersen M, Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia 2007; 13: 45161.
  • 5
    Croom KP, McCormack P. Recombinant factor Viia (Eptacog alfa). A review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders. Biodrugs 2008; 22: 12136.
  • 6
    Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicenter study. Thromb Haemost 1997; 78: 14637.
  • 7
    Baudo F, De Cataldo F, Gaidano G. Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia. Haematologica 2004; 89: 75961.
  • 8
    Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia 2004; 10: 16973.
  • 9
    Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 385864.
  • 10
    O’Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295: 2938.
  • 11
    Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA) – addressing safety issues. Haemophilia 2008; 14: 3943.
  • 12
    Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591605.
  • 13
    Guillet B, Pinganaud C, Proulle V, Dreyfus M, Lambert T. Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VII. Thromb Haemost 2002; 88: 6989.
  • 14
    Hilgartner MW, Knatterud G, the FEIBA study group. The use of factor-eight-inhibitor-by-passing-activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61: 36.
  • 15
    Kasper CK. Human factor VIII for bleeding in patients with inhibitors. Vox Sang 1999; 77(Suppl. 1): 478.
  • 16
    Muhm M, Grois N, Kier P et al. 1-Deamino-8-D-arginine vasopressin in the treatment of non-haemophilic patients with acquired factor VIII inhibitor. Haemostasis 1990; 20: 1520.
  • 17
    Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood 1995; 86: 797804.
  • 18
    Nemes L, Pitlik E. New protocol for immune tolerance induction in acquired hemophilia. Haematologica 2000; 85(10 Suppl.): 648.
  • 19
    Huth-Kühne A, Lages P, Hampel H, Zimmermann R. Management of severe hemorrhage and inhibitor elimination in acquired hemophilia: the modified Heidelberg-Malmö protocol. Haematologica 2003; 88(S12): 8692.
  • 20
    Zeitler H, Ulrich-Merzenich G, Hess L et al. Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood 2005; 105: 228793.
  • 21
    Lottenberg R, Kentro TB, Kitchens CS. Acquired haemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987; 147: 107781.
  • 22
    Green D, Lechner K. A Survey of 215 non-haemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981; 45: 2003.
  • 23
    Green D. Cytotoxic suppression of acquired factor VIII:C inhibitors. Am J Med 1991; 91(5A): 14S9S.
  • 24
    Delgado Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired hemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003; 121: 2135.
  • 25
    Bussi L, Baudo F, De Cataldo F. Factor VIII concentrate and cyclophosphamide in patients with factor VIII inhibitors. Blood 1974; 44: 767.
  • 26
    Green D, Rademaker AW, Briet E. A prospective randomized trial of prednisolone and cyclophosphamide in the treatment of patients with factor VIII antibodies. Thromb Haemost 1993; 70: 7537.
  • 27
    Sperr WF, Lechner K, Pabinger I. Rituximab for the treatment of acquired antibodies to factor VIII. Haemophilia 2007; 92: 6671.